for subcutaneous use Initial U.S. Approval: 2012
Ponatinib tablets is “used to treat patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI)“. ICLUSIG Tablets is a “prescription medicine”. It is available in “form and strength” Tablets: 15 mg and 45 mg. ICLUSIG Tablets can be obtained in India upon request.
To inquire about the ICLUSIG (ponatinib) tablets“offer price in India”, “shipping process”, and the “estimated time of availability in India”, please get in touch at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj). with the IPN Delhi healthcare team for further discussion.”
Facts about your medicine
Approval Date: 2012
Proprietary Name: On Request
Active Ingredient(s): Ponatinib tablets
Dosage Forms And Strengths:
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For Ponatinib tablets
Know about product usage and updates
Ponatinib, is a medication the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.
A drug used to treat adults with certain types of chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. It is used in patients whose cancer has the T315I mutation or whose cancer cannot be treated with other tyrosine kinase inhibitors. It is also being studied in the treatment of other types of cancer. Ponatinib hydrochloride blocks BCR-ABL and other proteins, which may help keep cancer cells from growing and may kill them. It may also prevent the growth of new blood vessels that tumors need to grow. Ponatinib hydrochloride is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.
Who is the supplier of Specialty drug in India?
Indian Pharma Network (IPN) Legitimate consultant and facilitator for Specialty drugs in India. IPN, Delhi can assist you in connecting with prospective distributors, wholesalers, suppliers, and dealers of ICLUSIG (ponatinib) tablets. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
ICLUSIG (ponatinib) tablets for oral use Initial U.S. Approval: 2012
Related posts for product review usage
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa